HUE043194T2 - PLK-4 inhibitor sója és kristályformái - Google Patents

PLK-4 inhibitor sója és kristályformái

Info

Publication number
HUE043194T2
HUE043194T2 HUE14854037A HUE14854037A HUE043194T2 HU E043194 T2 HUE043194 T2 HU E043194T2 HU E14854037 A HUE14854037 A HU E14854037A HU E14854037 A HUE14854037 A HU E14854037A HU E043194 T2 HUE043194 T2 HU E043194T2
Authority
HU
Hungary
Prior art keywords
plk
inhibitor
salt
crystalline forms
crystalline
Prior art date
Application number
HUE14854037A
Other languages
English (en)
Hungarian (hu)
Inventor
Peter Brent Sampson
Miklos Feher
Heinz W Pauls
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of HUE043194T2 publication Critical patent/HUE043194T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14854037A 2013-10-18 2014-10-17 PLK-4 inhibitor sója és kristályformái HUE043194T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361892564P 2013-10-18 2013-10-18

Publications (1)

Publication Number Publication Date
HUE043194T2 true HUE043194T2 (hu) 2019-08-28

Family

ID=52827507

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14854037A HUE043194T2 (hu) 2013-10-18 2014-10-17 PLK-4 inhibitor sója és kristályformái

Country Status (27)

Country Link
US (5) US9884855B2 (enExample)
EP (1) EP3057965B1 (enExample)
JP (1) JP6492072B2 (enExample)
KR (3) KR20160070106A (enExample)
CN (2) CN113248486A (enExample)
AU (1) AU2014336929B9 (enExample)
CA (1) CA2926845C (enExample)
CY (1) CY1121484T1 (enExample)
DK (1) DK3057965T3 (enExample)
EA (1) EA031569B1 (enExample)
ES (1) ES2718603T3 (enExample)
HR (1) HRP20190564T1 (enExample)
HU (1) HUE043194T2 (enExample)
IL (1) IL245038B (enExample)
LT (1) LT3057965T (enExample)
ME (1) ME03377B (enExample)
MX (1) MX359069B (enExample)
NZ (1) NZ718744A (enExample)
PL (1) PL3057965T3 (enExample)
PT (1) PT3057965T (enExample)
RS (1) RS58413B1 (enExample)
SG (1) SG11201602783SA (enExample)
SI (1) SI3057965T1 (enExample)
SM (1) SMT201900124T1 (enExample)
TR (1) TR201902875T4 (enExample)
TW (1) TWI659952B (enExample)
WO (1) WO2015054793A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
PT2556071T (pt) 2010-04-06 2016-11-22 Univ Health Network Inibidores de quinase e seus usos no tratamento de cancro
PT3057965T (pt) 2013-10-18 2019-04-23 Univ Health Network Formas de sal e cristal de inibidor de plk-4
TWI845482B (zh) 2017-09-08 2024-06-21 加拿大健康網路大學 用於抑制類polo激酶4之組合療法
BR112021021106A2 (pt) * 2019-04-24 2021-12-14 Univ Health Network Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona
CN115397429A (zh) * 2019-12-06 2022-11-25 大学健康网络 急性髓性白血病或骨髓增生异常综合征治疗
IL308346A (en) 2021-05-11 2024-01-01 Oric Pharmaceuticals Inc Polo like kinase 4 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483323A (en) * 1945-08-01 1949-09-27 Kay Fries Chemicals Inc Method of preparing phenyl ethyl alcohol
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US8227640B2 (en) * 2007-03-23 2012-07-24 Institute Of Bioengineering And Nanotechnology Palladium catalysts
NZ584760A (en) * 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
JP2011506494A (ja) * 2007-12-21 2011-03-03 ユニバーシティ・ヘルス・ネットワーク 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
CN102428086B (zh) * 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
PT2556071T (pt) 2010-04-06 2016-11-22 Univ Health Network Inibidores de quinase e seus usos no tratamento de cancro
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2012121764A1 (en) * 2010-11-25 2012-09-13 Ratiopharm Gmbh Novel salts and polymorphic forms of afatinib
CA2850394C (en) * 2011-10-12 2019-05-21 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
JP6525983B2 (ja) 2013-10-18 2019-06-05 ユニバーシティー ヘルス ネットワーク 膵癌の治療法
PT3057965T (pt) 2013-10-18 2019-04-23 Univ Health Network Formas de sal e cristal de inibidor de plk-4

Also Published As

Publication number Publication date
MX2016004963A (es) 2016-06-28
EA201690755A1 (ru) 2016-09-30
US20160264559A1 (en) 2016-09-15
IL245038B (en) 2019-11-28
SI3057965T1 (sl) 2019-04-30
TR201902875T4 (tr) 2019-03-21
TW201609717A (zh) 2016-03-16
US20190248775A1 (en) 2019-08-15
SMT201900124T1 (it) 2019-05-10
RS58413B1 (sr) 2019-04-30
HRP20190564T1 (hr) 2019-05-17
ME03377B (me) 2020-01-20
MX359069B (es) 2018-09-12
ES2718603T3 (es) 2019-07-03
TWI659952B (zh) 2019-05-21
US10472353B2 (en) 2019-11-12
JP2016537326A (ja) 2016-12-01
US9884855B2 (en) 2018-02-06
WO2015054793A1 (en) 2015-04-23
US20210269428A1 (en) 2021-09-02
SG11201602783SA (en) 2016-05-30
KR20210137251A (ko) 2021-11-17
CA2926845A1 (en) 2015-04-23
KR20220063299A (ko) 2022-05-17
PT3057965T (pt) 2019-04-23
CN105764899A (zh) 2016-07-13
DK3057965T3 (en) 2019-04-01
EP3057965A4 (en) 2017-05-24
EA031569B1 (ru) 2019-01-31
AU2014336929B9 (en) 2019-03-21
CN113248486A (zh) 2021-08-13
US20200140428A1 (en) 2020-05-07
US20180155335A1 (en) 2018-06-07
KR20160070106A (ko) 2016-06-17
EP3057965A1 (en) 2016-08-24
NZ718744A (en) 2021-07-30
KR102395737B1 (ko) 2022-05-10
LT3057965T (lt) 2019-03-12
EP3057965B1 (en) 2019-01-02
JP6492072B2 (ja) 2019-03-27
CA2926845C (en) 2023-06-13
US11667627B2 (en) 2023-06-06
AU2014336929B2 (en) 2018-11-22
US10919886B2 (en) 2021-02-16
IL245038A0 (en) 2016-05-31
US10392374B2 (en) 2019-08-27
PL3057965T3 (pl) 2019-08-30
CN105764899B (zh) 2021-06-01
CY1121484T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
IL267681B (en) Selective grp94 inhibitors and uses thereof
HUE057734T2 (hu) Heterociklusos vegyületek és alkalmazásuk
HUE040434T2 (hu) Szelektív CDK4/6 inhibitor szilárd alakjai
IL240967A0 (en) Inhibitors of the kynurenine pathway
SMT201700363T1 (it) Inibitori di bromodominio cristallini
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
LT3290407T (lt) Bromodomeno inhibitoriai
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
DK3043785T3 (da) Anvendelse af r-ketamin og salt deraf som lægemidler
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
HUE042466T2 (hu) Eljárás és köztitermékek JAK inhibitor elõállítására
HUE046285T2 (hu) Omecamtiv mecarbil sói és eljárás a só elõállítására
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
HUE053047T2 (hu) MDM2 inhibitor kristályos formája
SI3293176T1 (sl) Kristalna oblika inhibitorja PDE4
DK2958926T3 (da) Epidithiodioxopiperazinforbindelse eller derivater deraf og anvendelse deraf
EP3071554A4 (en) Crystalline forms of lesinurad and its sodium salt
HUE043194T2 (hu) PLK-4 inhibitor sója és kristályformái
DK3066089T3 (da) Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser
HUE056048T2 (hu) Helyettesített pirimidin vegyületek és SYK inhibitorként való alkalmazásuk
TH1401007310A (th) เอไมด์ของสารประกอบ 2-อะมิโน-4-เอริลไธอะโซลและเกลือของสารประกอบดังกล่าว
TH1501001781A (th) สารประกอบเตตระโซลิโนน และการใช้ของสิ่งนั้น
TH1501001044A (th) เกลือแอมีน และผลึกของสารนั้น
UA28690S (uk) Ендопротез голівки променевої кістки